Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C by Childs, Kate et al.
Research Article
JOURNAL 
OF HEPATOLOGYSuboptimal SVR rates in African patients with atypical
genotype 1 subtypes: Implications for global
elimination of hepatitis CGraphical abstracthttp://dx.doi.org/10.1016/j.jhep.2019.07.025
 2019 European Association for the Study of the Liver. Published by Elsevier B.V. Th
creativecommons.org/licenses/by/4.0/). J. Hepatol. 2019, 71, 1099–1105Authors• SVR was achieved in 56/63
(89%) overall
• SVR in only 21/28 (75%) of
those with unusual G1
subtypes
• Failure in 3/16 G1*, 1/2
G1p and 3/3 in G1l.
• Six treatment failures
were with SOF/LDP
compared with one failure
on a PI based regimen.G1
a/1
b
G1
 no
n 1
a/1
b G2 G3 G4
G4
 no
n 4
a/4
d
G5
/6
0
50
100
150
SV
R
 ra
te
 %
• Pre-treatment
sequences were
available on 22 unusual
G1 patients. 18/22
(82%) had NS5A
resistance associated
substitutions (RASs).
• Of 91 African patients,
47 (52%) were infected
with an unusual
subtype
39%
22%13%
16%
G1a/1b
G1 non 1a/1b
G2
G3
G4
G4 non 4a/4d
G5/6
• Rare HCV subtypes are underrepresented in clinical trials but are
prevalent in some regions
• 15% of global HCV cases are in the WHO African Region
• Aim: to describe the genotype distribution and antiviral
treatment outcome in a south London cohort of African patients
• Unusual subtypes were defined as non 1a/1b/ non-subtypeable
genotype 1 (G1) or non 4a/4d G4
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14 novel, as yet undesignated subtypes (G1*) were identified by
Next Generation Sequencing. Three individuals were infected with
the same subtype, now designated as subtype 1p
In this African cohort  unusual and previously undescribed subtypes were
common. There was a high degree of viral diversity there was a lower SVR rate in
those with unusual African subtypes, particularly in those who received a first
generation NS5A inhibitor.
Highlights
 Unusual genotypes (G1 non 1a/1b or G4 non 4a/4d) were
common in African patients.
 11 previously unclassified HCV subtypes were represented
including novel G1p.
 Patients with unusual G1 subtypes had a lower SVR rate than
any other genotype.
 Failures were driven by patients treated with a first gener-
ation NS5A inhibitor.
 The majority of unusual G1 subtypes had baseline NS5A
resistance mutations.Kate Childs, Christopher Davis, Mary Can-
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Lay summary
Direct-acting antiviral medications are
able to cure hepatitis C in the majority
of patients. The most common genotype
of hepatitis C in Europe and the United
States is genotype 1a or 1b and most
clinical trials focused on these genotypes.
We report that in a group of African
patients, most of them had unusual
(non-1a/1b) genotype 1 subtypes, and
that the cure rate in these unusual geno-
types was lower than in genotypes 1a and
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types. We report that in a group of African patients, most of
them had unusual (non-1a/1b) genotype 1 subtypes, and that
the cure rate in these unusual genotypes was lower than in
genotypes 1a and 1b.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Direct-acting antiviral therapy (DAA) therapy has revolu-
tionised hepatitis C (HCV) treatment. High cure rates with short
courses of treatment make global eradication of HCV feasible;
consequently, the World Health Organisation has promulgated
a call for elimination of viral hepatitis as a public health threat
by 2030.1
With 11 million people infected, HCV has an estimated
prevalence of 1% in the African region.1 Despite this, there have
been few clinical trials conducted in African cohorts and data is
lacking on the prevalence, geographical distribution and treat-
ment response of African sub-genotypes.2,3
There are 8 known HCV genotypes which have been classi-
fied based on the analysis of HCV genetic sequences.4 Except
for genotypes 5 and 8, each genotype is further divided into a
number of subtypes. A genome-wide nucleotide sequence dif-
ference of 31–33% is considered sufficient to differentiate a
genotype and a difference of 12–15% is sufficient to distinguish
a sub-genotype (or subtype), although these boundaries are not
strict and phylogeny is also considered.
Clinical trial and real-life data routinely report sustained
virological response (SVR) rates in excess of 95% for genotype
1a, (G1a) 1b, 3 and 4. There are fewer data available on less
prevalent genotypes such as 5 or 6, nor are unusual subtypes
well represented. In an analysis of over 1,700 patients with
genotype 1 HCV, who had been enrolled in clinical trials of
NS5A inhibitors, less than 1% had subtypes of genotype 1 other
than 1a or 1b.5 The available evidence suggests that other geno-
type 1 subtypes are common in Africa but less frequent in the
industrialised countries where clinical trials have been cen-
tred.6,16 In this paper we refer to these as ‘‘unusual genotypes”.
We choose this nomenclature for clarity as these genotypes are
unusual in Europe, but not unusual in Africa, as we will discuss.
However, there is a paucity of data as to whether the treatmentUnited Kingdom; Nuffield Department of Medicine, Univer
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Background & Aims: HCV subtypes which are unusual in Eur-
ope are more prevalent in the African region, but little is known
of their response to direct-acting antivirals (DAAs). These
include non-1a/1b/ non-subtypeable genotype 1 (G1) or non-
4a/4d (G4). In this report we aimed to describe the genotype
distribution and treatment outcome in a south London cohort
of African patients.
Methods:We identified all patients born in Africa who attended
our clinic from 2010-2018. Information on HCV genotype, treat-
ment regimen and outcome were obtained. Non-subtypeable
samples were analysed using Glasgow NimbleGen next-
generation sequencing (NGS). Phylogenetic analysis was carried
out by generating an uncorrected nucleotide p-distance tree
from the complete coding regions of our sequences.
Results: Of 91 African patients, 47 (52%) were infected with an
unusual subtype. Fourteen novel, as yet undesignated subtypes
(G1*), were identified by NGS. Three individuals were infected
with the same subtype, now designated as subtype 1p. Baseline
sequences were available for 22 patients; 18/22 (82%) had base-
line NS5A resistance-associated substitutions (RASs). Sustained
virological response (SVR) was achieved in 56/63 (89%) overall,
yet only in 21/28 (75%) of those with unusual G1 subtypes, with
failure in 3/16 G1*, 1/2 G1p and 3/3 in G1l. Six treatment fail-
ures occurred with sofosbuvir/ledipasvir compared to 1 failure
on a PI-based regimen. The SVR rate for all other genotypes
and subtypes was 35/35 (100%).
Conclusions:Most individuals in an unselected cohort of Afri-
can patients were infected with an unusual genotype, including
novel subtype 1p. The SVR rate of those with unusual G1 sub-
types was 75%, raising concern about expansion of DAAs across
Africa. Depending on the regimen used, higher failure rates in
African cohorts could jeopardise HCV elimination.
Lay summary: Direct-acting antiviral medications are able to
cure hepatitis C in the majority of patients. The most common
genotype of hepatitis C in Europe and the United States is geno-
type 1a or 1b and most clinical trials focused on these geno-
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and paired end sequencing carried out on an Illumina MiSeq
instrument using 300-cycle v2 reagents. De novo assembly
Research Article Viral Hepatitisresponse in patients with these less well characterised subtypes
is comparable to more common subtypes. This has led to calls
for more treatment outcome data in well characterised cohorts
of patients.7,8
Our institution serves a population of high ethnic diversity
with a high prevalence of chronic hepatitis C infection. In this
analysis we report the distribution of HCV genotypes and sub-
types according to country of birth and treatment outcomes in
an immigrant population cohort of patients born in Africa.
Patients and methods
Patients
This is a retrospective cohort study of all patients with hepatitis
C at our centre who originate from the continent of Africa. We
performed a search of our clinical database to identify all
patients who were born in Africa, were infected with HCV and
who accessed care between 2010 and 2018. For comparison,
we also collected available information on the ethnicity and/or
country of birth of all patients attending our clinic with HCV
infection during the same time period. The study was approved
by the Health Research Authority of England and Wales.
Clinical data
We report on the genotypes, subtypes and treatment outcome
in this group. The choice of hepatitis C treatment for all patients
was discussed at a hepatitis multidisciplinary meeting and
based on NHS England guidance. Data was gathered on the
DAA regimen used including the use of ribavirin, the degree of
hepatic fibrosis and the individuals’s HIV status. SVR was
defined as an undetectable HCV RNA by sensitive polymerase
chain reaction 12 and 24 weeks after cessation of treatment.
Virological assays
HCV RNA was determined by the Roche COBAS AmpliPrep/
COBAS TaqManTM HCV Test, v2.0 assay with a sensitivity of
15 IU/ml.
For all patients, HCV genotyping was performed using the
VERSANT HCV Geno 2.0 assay at our in-house tertiary viral hep-
atitis laboratory. Where samples could not be subtyped beyond
belonging to genotype 1, they were designated ‘unassigned
genotype 1’. These were sent to the MRC-University of Glasgow
Centre for Virus Research, Glasgow for next-generation
sequencing (NGS) with the aim of identifying the subtypes.
In this paper, we refer to all non-1a/1b/unassigned genotype 1
or non-4a/4d genotype 4 samples as ‘‘unusual African subtypes”.
We use this term forwant of amore precise label, as the epidemi-
ological association with the region has been established. Many
but not all of the identified sequences have been provisionally
assigned genotypes; the majority of which have been given a
notation based on sequences isolated from sub-Saharan, or North
Africa. The word unusual refers to the low frequency with which
these subtypes are seen in European treatment centres.
Next-generation sequencing
NGS was carried out using a target enrichment sequencing pro-
tocol as previously described.9 Briefly, RNA was extracted from
200 ll plasma using the Agencourt RNAdvance Blood kit (Beck-
man Coulter) and reverse transcribed using SuperScript III
(Invitrogen) with random hexamers and a NEB Second Strand
Synthesis kit (New England Biolabs). Adapter-ligated DNA was
amplified in real-time on an ABI 7500 cycler, using a KAPA Hifi
1100 Journal of Hepatology 20Real-time library amplification kit. Index tags were added using
NEBnext multiplex oligos (New England BioLabs). Pooled
libraries were enriched using the NimbleGen SeqCap EZ system
(Roche). Amplified DNA was purified using AMPure XP beads
and eluted in a final volume of 15 ll. AnAgilent 2200 TapeSta-
tion was used to verify the final size profile of amplified library
DNA. DNA libraries with appropriate index tags were pooledwas carried out using dipSPAdes and mapping with Tanoti
(http://www.bioinformatics.cvr.ac.uk/tanoti.php). Sequence
data were submitted to GenBank (accession numbers to follow).
Table 1. Demographics and clinical parameters. HCV genotypes are shown
according to country of birth.
Parameter N = 91
Age 54 (47, 64)
Sex 42 (46%) female, 49 (54%) male
HIV positive 8 (9%)
Fibroscan (kPa)
median (IQR)
6.1 (5.1, 8.7)
Cirrhosis 21/91 (23.1%)
Country of birth n (genotype by country)
Angola 1 (4)
Benin 1 (1*)
Cameroon 8 (1*, 1b, 1e, 1e, 1e, 1l, 4, 4f)
Chad 1 (1e)
Democratic
Republic of Congo
7 (2, 4, 4c, 4f, 4k, 4k, 4r)
Ivory Coast 5 (1a, 1a, 1*, 1*, 1*)
Egypt 4 (1g, 1g, 4, 4)
Eritrea 4 (1a, 4a/c/d, 4r, 5a)
Ethiopia 2 (4e, 4e)
Ghana 7 (1a, 1a, 1b, 1*, 1*, 2a/c, 4)
Mauritius 2 (1a, 1a)
Nigeria 34 (1a, 1a, 1a, 1*,1*, 1*, 1*, 1*, 1*, 1*, 1*, 1*, 1*, 1*,
1p, 1p, 1p, 1b, 1b, 1b, 1b, 1g, 1g, 1g, 1h, 1l, 1l, 3a, 4,
4, 4a/c/d, 4a, 4f)
Sierra Leone 2 (2k or 1b/2k, 2a or 2c)
Somalia 4 (3h, 3h, 4e, 6)
Sudan 1 (4e)
Tanzania 1 (1b)
Tunisia 2 (1a, 1*)
Uganda 2 (1a, 4)
African, country
not known
3 (1a, 4, 4a/c/d)
2.13 any other Asian background
3.62 any other black background
0.50 Chinese
0.95 Indian
0.50 Ireland
1.22 Irish
1.09 Italy
0.27 not stated
0.77 Pakistan
0.63 Poland
0.36 Spain
14.88 United Kingdom
0.36 Vietnam
3.53 other
4.12 black African
5.56 any other ethnic group
1.54 any other mixed background
22.57 any other white background
30.57 British
1.72 Caribbean
0.41 Jamaica
1.94 Pakistani
0.77 Portugal
Distribution of ethnicity/race (%)
Fig. 1. Distribution of ethnicity/race of all patients (n = 2,211) with HCV
attending our centre between 2010 and 2018. (This figure appears in colour
on the web.)
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An uncorrected nucleotide p-distance tree was generated using
MEGA 7.0 from the complete coding regions of our sequences
after alignment using MAFFT with a reference set of subtypes,
including unassigned genotype 1 sequences. Maximum likeli-
hood phylogenetic analysis was carried out using RaxML and
the best fit model (GTR+G+I).
Statistical analysis
Continuous variables were reported as median (interquartile
range). Categorical univariate analysis was carried out using
Chi Square and Fishers exact test. Analysis was performed using
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Fig. 2. Distribution of HCV genotype amongst 91 African patients (white
bars) compared to the rest of the HCV cohort (blue bars).
Journal of Hepatology 20SPSS Statistics v25. When performing multivariate analysis, the
small numbers led to issues of separation in the data therefore
bias-reduced penalized-likelihood logistic regression (Firth
1993) was used.10 This was implemented in the ’logistf’ R pack-
age and penalized-likelihood ratio tests were used to assess sig-
nificance.11 Variables with a p value of <0.05 in univariate
analysis were included in multivariate analysis.
Results
Sub-genotypes prevalent in African patients
The total number of patients with HCV seen at our centre
between 2010 and 2018 was 2,211, of whom we identified 91
(4.1%) patients who were born in Africa, the majority from
sub-Saharan Africa (Table 1). The ethnicity or country of birth
of the whole HCV cohort are shown in Fig. 1. Amongst the Afri-
can patients 20/91 (22%) patients were infected with genotype
1a or 1b, 35 (39%) patients had unusual African genotype 1 sub-
types, including sub-genotypes 1e, 1g, 1h, 1l, and 23 patients
had unassigned genotype 1. Five patients (5.6%) were infected
with genotype 2; 3 (3.3%) were infected with genotype 3; 14
(15.6%) had genotype 4; 12 (13.1%) were infected with unusual
subtypes of genotype type 4, including 4c, 4e, 4f, 4k, 4r; 2
patients had genotype 5 and 6 infection. The frequency of
HCV genotypes of the whole cohort compared to the African
group are shown in Fig. 2. Of the non-African patients, who were
predominantly British born, but also included Asian, Caribbean
and other European backgrounds, 38.7% were infected with
genotype 1a, 15.2% with G1b, 30.4% with G3a and only 3.3%
with unassigned G1.
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In the African cohort, HCV genotypes according to country of
birth are shown in Table 1 and Fig. 3. Of the 23 unassigned
genotype 1 samples that underwent NGS, 18 complete open
reading frame sequences from 15 novel unassigned subtypes
were identified. Formal HCV sub-genotype assignment and clas-
sification requires at least 3 epidemiologically unrelated iso-
lates.4 We met this recognised criterion with samples from 3
individuals from Nigeria, shown on the p-distance tree as
Patient (P)15, P17, and P38. Two of the patients were a married
couple, however phylogenetic analysis indicated that they were
infected with different variants of the same subtype. This novel
subtype has been assigned as 1p. It should be noted that 1 of our
patients who failed treatment with sofosbuvir and ledipasvir,
P17, was infected with the newly identified genotype 1p.
Of our remaining unassigned 14 subtypes, 3 had pairs of
unrelated sequences and the remainder only 1 unrelated
sequence. We refer to these novel unclassified subtypes as
G1*. These are shown on the phylogenetic tree in Fig. 4.
Treatment response
To date, 63 patients have completed DAA treatment and follow-
up. Fifty-six of these patients have achieved an SVR, while 7
failed treatment, giving an overall SVR rate of 89%. As expected,
response rates in genotypes 1a or 1b were uniformly high. Sim-
ilarly, all patients infected with genotype 2, 3, 4 and 5 achieved
an SVR. In those patients with unusual G1 and G4 African sub-
types, treatment response according to genotype and choice of
treatment regimen are shown in Table 2. An SVR was observed
in only 21 of the 28 (75%) patients infected with unusual African
genotype 1.
Five patients who failed initial treatment have thus far com-
menced retreatment: 3 of these patients have completed
16 weeks of glecaprevir and pibrentasvir, 2 of whom have
achieved an SVR. One individual with cirrhosis and G1* HCV
virus failed to achieve an SVR with 16 weeks of glecaprevir
and pibrentasvir. Two other patients were retreated with sofos-
buvir, velpatasvir and voxilaprevir and achieved an SVR.
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Table 2. HCV treatment outcomes according to genotypes in African patients.
Genotype Proportion treated Treatment SVR rate SVR (NS5A based) SVR (PI
based)
1a/1b 12/12 (100%) 2/2 (100%) 10/10 (100%)
1a and 1b 12/20 2 Sofosbuvir/ledipasvir
7 Paritaprevir/ritonavir/ombitasvir dasabuvir
3 Grazoprevir/elbasvir
2/2
7/7
3/3
Distinct G1 subtypes 21/28 (75%) 9/15 (60%) 12/13 (92%)
1* 16/22 7 Sofosbuvir/ledipasvir 5/7
6 Paritaprevir/ritonavir/ombitasvir dasabuvir 6/6
3 Grazoprevir/elbasvir 2/3
1e 2/4 1 Sofosbuvir/ledipasvir 1/1
1 Grazoprevir/elbasvir 1/1
1g 5/5 3 Sofosbuvir/ledipasvir 3/3
1 Paritaprevir/ritonavir/ombitasvir dasabuvir
1 Grazoprevir/elbasvir
1/1
1/1
1l 3/3 3 Sofosbuvir/ledipasvir 0/3
1p 2/3 1 Sofosbuvir/ledipasvir
1 Paritaprevir/ritonavir/ombitasvir dasabuvir
0/1
1/1
G4 subtypes 14/14 (100%) 2/2 (100%) 12/12 (100%)
Unknown 4 8/10 4 Paritaprevir/ritonavir/ombitasvir
4 Grazoprevir/elbasvir
8/8
4e 3/4 1 Sofosbuvir/ledipasvir
1 Paritaprevir/ritonavir/ombitasvir,
1 Grazoprevir/elbasvir
3/3
4f 2/3 1 Sofosbuvir/velpatasvir
1 Grazoprevir/elbasvir
2/2
4k 1/2 1 Paritaprevir/ritonavir/ombitasvir 1/1
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A univariate categorical analysis was carried out to investigate
which factors were associated with response. The presence of
an unusual genotype 1 African subtype or the use of an NS5A
inhibitor-based regimen were both significantly associated with
a lack of SVR in univariate analysis, no other factors were. The
results are shown in Table 3.
In multivariate analysis with SVR as the outcome variable,
unusual genotype 1 remained highly significant with a p value
of 0.016 (Chi-Squared: 5.78, df = 1), treatment regimen (NS5A
inhibitor-based vs. protease inhibitor) was close to significant
with a p value of 0.054 (Chi-Squared: 3.69, df = 1).
HCV sequence results
Baseline sequence data was available for 22 patients, 14 who
achieved SVR, 6 treatment failures, 2 who have not yet been
Table 3. Factors associated with achieving an SVR.
SVR
No Yes p value by univariate analysis
Genotype
Unusual G1 7 21 0.002
Any other genotype 0 35
Treatment regimen
NS5a 6 16 0.008
Protease inhibitor based 1 40
Cirrhosis
No 4 46 0.135
Yes 3 10
Ribavirin use
No 4 23 0.6
Yes 3 33
HIV positive
No 6 49 1.0
Yes 1 6
PI, protease inhibitor; SVR, sustained virological response.SVR, sustained virological response.
Journal of Hepatology 20treated. There were numerous NS5A polymorphisms present
at baseline in patients with unusual G1 subtypes, particularly
at positions 24, 30 and 31. Resistance-associated substitutions
(RASs) listed in the EASL 2018 HCV guidelines as conferring
reduced susceptibility to NS5A inhibitors or being associated
with reduced treatment response were seen at baseline in
18/22 (82%) patients. All the treatment failures had either
M28 polymorphisms (L and S) (2 failures) or L31M (4 failures).
Five SVR patients had M28 (L and V), 3 patients (2 with 1* and 1
with 1g) who achieved SVR had Y93 (F/H/N) at baseline. These
data are expanded in Table 4. The individual patient with 1*
who has failed treatment with both sofosbuvir/ledipasvir and
then glecaprevir/pibrentasvir had Q62E, L31M at baseline and
Q62D, L31M following SOF/LDV. Following glecaprevir/pibren-
tasvir treatment Q30H, H58S and Y93H were also accumulated.
Discussion
In this analysis we report the prevalence of HCV genotypes in a
consecutive cohort of 91 African patients from 18 countries,
documenting the outcome of DAA therapy in patients with sub-
types of genotype 1 and 4 that are prevalent in Africa but unu-
sual in the West. Our study has 3 main findings. Firstly, unusual
and previously undescribed subtypes were common. Secondly,
there was a high degree of viral diversity and thirdly there
was a lower SVR rate in those with unusual African subtypes,
particularly in those who received a first generation NS5A
inhibitor.
In this unselected cohort of immigrant African patients, 47 of
91 (52%) were infected by unusual African subtypes, (i.e. G1
non-1a/1b/ unassigned G1 subtype, or with G4 other than 4a
or 4d). The distribution of genotypes was different from the
non-African majority of our HCV patient cohort where G1a
and 3a were the most common. The finding that unusual sub-
types were common amongst African patients mirrors the
19 vol. 71 j 1099–1105 1103
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Research Article Viral HepatitisTable 4. NS5A polymorphisms present at baseline and post treatment failu
SVR Genotype Baseline p
No 1l K24G, L31
No 1l K24S, L31
No 1l K24G, Q30
No 1* M28L, H58
No 1p M28S, Q30
No 1* Q62E, L31
Yes 1* Q62D, H58
Yes 1g K24R, M2
Yes 1e K24Q, M2
Yes 1* K24G, H58
Yes 1* M28L, Q30
Yes 1* M28V, H5
Yes 1* K24Q, Q62
Yes 1* S38A, H58
Yes 1* Q62E
Yes 1* M28V, Q3
Yes 1* H58P
Yes 1* K24Q, M2
Yes 1* K24Q, M2
Yes 1* H58P
Untreated 1* K24S, H58
Untreated 1* K24K, L31M
G1 RASs as per 2018 EASL HCV Guidelines are in bold font. RAS, resistance-associatedresults from the Los Alamos HCV database which contains 288
sequences of genotype 1c to 1m; 47.4% of these isolates origi-
nated in Africa.12 The fact the majority of catalogued non-1a/b
G1 subtypes originated in Africa and that the majority of our
cohort were infected with unusual subtypes suggests that these
subtypes are more common in Africa than Europe. Since 15% of
global cases of HCV are based in the WHO African region,1 these
variants of HCV could be numerically significant. Population-
based studies are required to establish the true prevalence of
these ‘‘unusual” subtypes in Africa.Our second finding was the high diversity of HCV sequences.
We were able to sequence 15 previously undescribed subtypes
of G1 HCV. One of these sequences was found to be a strain
infecting 3 different patients, allowing formal classification as
the novel genotype 1p. This is concordant with recent data from
a cohort from Uganda and the Democratic Republic of Congo,
where highly diverse genotype 4 and 7 strains, including uncon-
firmed novel strains were recently identified.2 We can speculate
that the diversity of HCV observed in this cohort and other stud-
ies, if confirmed by larger phylogenetic analyses, perhaps points
to an early evolutionary origin of human hepatitis C genotype 1
and 4 in Africa.13
We observed a high number of resistance-associated poly-
morphisms in pre-treatment samples from our cohort. NS5A
RASs listed in the 2018 EASL guidelines as conferring reduced
susceptibility to NS5A inhibitors, for example at positions 24,
28, 30 and 31 were present in 82% of patients with baseline
sequence data.14 This contrasts with published findings from
the pooled analysis of phase II and III studies of sofosbuvir
and ledipasvir; of 2,108 patients only 16% patients had detect-
able baseline RASs.15 That we saw such high frequencies of
polymorphisms further demonstrates the diversity of the virus
in the African region.
Our third finding was that SVR rates were markedly lower in
this population. Although we have studied a relatively small
number of patients, we show that the overall SVR rate for Afri-
can patients at an experienced centre (89%), is lower than
1104 Journal of Hepatology 20expected in a group of predominantly non-cirrhotic patients.
Importantly the SVR rate fell to 21/28 (75%), in those infected
with non-1a/b G1 subtypes. The low SVR rate was driven by 6
failures in patients treated with sofosbuvir and ledipasvir, 1 fail-
ure with a protease inhibitor-based regimen and was associated
with multiple baseline polymorphisms.
There is limited data available on treatment outcome in
these uncommonly encountered genotypes. Zeuzem et al. have
reported 25 patients with genotype 1 (1c/e/g/h/l) who all
achieved SVR with an NS5a inhibitor-based regimen.8 These
results were considered reassuring. It should be noted, however,
that 18 patients received either sofosbuvir and velpatasvir,
(7 with voxilaprevir) or 24 weeks of sofosbuvir and ledipasvir.
Therefore, the majority of patients received the most potent
treatment currently available, or else lengthened courses of
treatment.
The French National Reference Centre recently reported that
genotype 4r is associated with a lower response rate to DAAs.
Five percent of all treatment failures were in patients infected
with G4r, although this subtype is rare in the French population
overall. Treatment failure was associated with multiple NS5A
RASs which were present in all those analysed at baseline, sim-
ilarly to our cohort.16 Gupta et al. recently published a large
scale single arm trial in Rwanda showing that genotype 4r, pre-
sent in 16% of participants, was associated with high rates of
unsuccessful treatment with sofosbuvir and ledipasvir, despite
good adherence.17 This has been linked to the presence of an
amino acid motif, MPRMP, at positions 28-32 of the NS5A gene
that confers high-level resistance to DAAs in vitro.18
Population-based studies to determine the frequency of unu-
sual subtypes and the efficacy of DAA regimens against them,
are urgently needed to formulate guidelines for treating HCV
in Africa.19 The corollary of these data, and the fact that in
resource poor regions of Africa genotyping or full genome
sequencing will not be available, is that second generation
e, where applicable.
lymorphisms Post-treatment RAS
, H58P K24G, M28L, L31M, H58P,
, H58P, K24S, L31M, H58P,
, L31M, H58P K24G, Q30R, L31M, H58P
, Q62D M28F, H58P, Q62D,
, H58P, Q62P M28S, Q30L, H58P, Q62D
, H58P, Q62D, L31M
n.a.
, H58P, Y93F n.a.
, Q30R, L31M, H58P, A92T n.a.
n.a.
, L31M, H58P n.a.
, Q62D n.a.
, Y93H, H58P n.a.
Q62D n.a.
n.a.
, H58P, Y93N n.a.
n.a.
, Q30L, H58P, Q62K, L31M n.a.
, Q30R, H58P, n.a.
n.a.
n.a.
H58P, n.a.
substitutions; SVR, sustained virological response.NS5A inhibitors should be preferred as first-line agents in the
region. Use of second-line NS5A inhibitors seems to overcome
19 vol. 71 j 1099–1105
resistance.20 However further evaluation of the efficacy of
newer regimens including sofosbuvir-velpatasvir or
glecaprevir-pibrentasvir against the genotype 1 and 4 subtypes
characterised in our analysis, is necessary. It has been suggested
that a triple DAA regimen, including a protease inhibitor is
required as first-line treatment.16,21
We have shown that in a metropolitan United Kingdom
cohort of African patients with HCV, most patients were
infected with unusual and often novel African subtypes which
were associated with reduced SVR rates. The reality of global
migration means that these data are also relevant for clinicians
in high income countries who should exercise caution in select-
ing regimens for African patients with unusual or un-
subtypeable genotypes.
The evidence indicates that the future desired expansion of
HCV treatment in Africa may risk unacceptable rates of failure
if first generation NS5A inhibitors are utilised without appropri-
ate epidemiological and viral sequence data. Global equity of
access to curative treatment is required to avoid jeopardising
the hepatitis C elimination agenda.
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